MRG-007

N/A

Report date: 2025/06/23 20:01:06

Base Information

Drug NameMRG-007
Drug Alias NameMRG-007ARR-217
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Cadherin-17DNA topoisomerase I inhibitors
TargetsCadherin-17DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLepu Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesArriVent Biopharma IncLepu Biopharma Co Ltd
Inactive CompaniesShanghai Miracogen Inc
Active IndicationsSolid tumoursNeoplasm MetastasisPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A